Michael Gillespie
Investment Director at RA Capital Management
Boston, Massachusetts
Overview
Work Experience
Investment Director
2022 - Current
Senior Associate
2022 - 2022
Associate
2020 - 2022
RA Capital Management is an investment advisor specializing in the life-sciences and drug development sectors.
Board Director
2023
Pluton Biosciences tests and discovers microbes for the production of a variety of products, primarily pesticides, and pharmaceuticals.
Raised $23,198,000.00 from RA Capital Management, iSelect Fund, Grantham Foundation, Radicle Growth, Illumina Ventures, First In Ventures, Fall Line Capital and Wollemi.
Board Director
2022
NAPIGEN is a biotechnology company that addresses novel genome engineering of various organisms such as plants, microbes, and animals.
Raised $7,850,000.00 from U.S. Department of Agriculture.
Board Director
2022 - 2024
Board Observer
2023 - 2024
GentiBio is a biotherapeutics company developing engineered regulatory T cells programmed to treat autoimmune allergic diseases.
Raised $177,000,000.00 from JDRF T1D Fund, Novartis Venture Fund, RA Capital Management, Avidity Partners, Seattle Children’s, Matrix Capital Management and OrbiMed.
Board Observer
2022 - 2023
Co Director of Texas Healthcare Challenge
2018 - 2020
Product Development
2017 - 2019
Founded to explore and define the limits to human functional capacity in health and disease, with the objective of improving the quality of life for human beings of all ages.
Aerospace Medicine Clerk
2019 - 2019
The Aerospace Medicine Clerkship is a research-based program with formal lectures on space medicine topics and issues, as well as familiarization with the medical aspects of International Space Station operations, design, and function.
Technology Commercialization Intern
2016 - 2018
Manages UT Southwestern's technology transfer activities and facilitates the formation of biomedical companies based on UT Southwestern-developed technologies.